Navigation Links
Cardiome Reports 2009 Results
Date:3/9/2010

legislation that may not be based on historical fact, including without limitation statements containing the words "believe", "may", "plan", "will", "estimate", "continue", "anticipate", "intend", "expect" and similar expressions. Such forward-looking statements or information involve known and unknown risks, uncertainties and other factors that may cause our actual results, events or developments, or industry results, to be materially different from any future results, events or developments expressed or implied by such forward-looking statements or information. Such factors include, among others, our stage of development, lack of product revenues, additional capital requirements, risk associated with the completion of clinical trials and obtaining regulatory approval to market our products, the ability to protect our intellectual property, dependence on collaborative partners and the prospects for negotiating additional corporate collaborations or licensing arrangements and their timing. Specifically, certain risks and uncertainties that could cause such actual events or results expressed or implied by such forward-looking statements and information to differ materially from any future events or results expressed or implied by such statements and information include, but are not limited to, the risks and uncertainties that: we may not be able to successfully develop and obtain regulatory approval for vernakalant (iv) or vernakalant (oral) in the treatment of atrial fibrillation or any other current or future products in our targeted indications; our future operating results are uncertain and likely to fluctuate; we may not be able to raise additional capital; we may not be successful in establishing additional corporate collaborations or licensing arrangements; we may not be able to establish marketing and sales capabilities and the costs of launching our products may be greater than anticipated; we rely on third parties for the continued supply and manufacture of
'/>"/>
SOURCE Cardiome Pharma Corp.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine news :

1. Cardiome Pharma Corp. Permitting Automatic Securities Disposition and Purchase Plans
2. Cardiome Announces Investigational Candidate, Vernakalant, Meets Primary Endpoint in European Comparator Study
3. Cardiome to Release Third Quarter Results
4. Cardiome And Astellas Announce Initiation Of Patient Enrolment In ACT 5 Trial
5. Orexigen(R) Therapeutics Presents New Data Showing Weight Loss with Contrave Significantly Improves Important Markers of Cardiometabolic Risk
6. Cardiome Pharma Corp. Announces Final Results of Tender Offer
7. Cardiome Pharma Corp. Announces Commencement of US$27.5 Million Tender Offer
8. Cardiome Announces Upcoming Presentation Of Results Of Phase 2b Clinical Trial Of Vernakalant (Oral) At The European Society Of Cardiology Congress 2009
9. Cardiome Pharma Corp. Announces Tender Offer To Purchase Up To US$27.5 Million Of Its Common Shares
10. Atherotech Adds New Cardiometabolic Tests Amid Strong 2009 Growth
11. Cardiome to Hold Conference Call
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/31/2014)... 2014 Daily Gossip writes in its Xtreme ... as the fastest fat loss program ever developed. It promises ... month. , There is no wonder after all that this ... time. The new nutrition and workout fat loss program was ... , According to the author of this fat loss ...
(Date:10/31/2014)... At the start of 2014, numerous news ... monoxide poisoning in their homes. Now, as 2015 (and ... Missouri-based heating and cooling company is taking a more ... the home heating season with the assurance that their ... Nov. 1, 2014, E and Q Heating and Cooling ...
(Date:10/31/2014)... 31, 2014 Energy Textiles has recently ... new gear is now available online, and Energy Textile ... of Celliant infrared-active athletic gear over compression gear. , ... contract has been signed for Under Armour to provide ... next eight years. In light of this decision, Energy ...
(Date:10/31/2014)... Oct. 31, 2014 (HealthDay News) -- Obesity increases the ... black and Hispanic women, two new U.S. studies show. ... found being overweight or obese increased the risk for ... women. "We,ve known this for a long time ... also in Hispanic women," study author Esther John, a ...
(Date:10/31/2014)... four older Americans say that either they or a ... according to the latest issue of The Gerontological Society ... ( PP&AR ), which goes on to show that ... to honor patients, end-of-life health care wishes. , This ... and Options ," features 12 articles that present new ...
Breaking Medicine News(10 mins):Health News:Xtreme Fat Loss Diet Review Reveals How to Transform Your Body in 25 Days 2Health News:Many Homeowners Missing Key Safety Risks with Home Heating;Missouri-based Company E and Q Announces New Safety Check 2Health News:Many Homeowners Missing Key Safety Risks with Home Heating;Missouri-based Company E and Q Announces New Safety Check 3Health News:Compression Gear--Is There a Better Alternative? 2Health News:Compression Gear--Is There a Better Alternative? 3Health News:Compression Gear--Is There a Better Alternative? 4Health News:Study Confirms Obesity-Breast Cancer Link for Blacks, Hispanics 2Health News:Advance directives can benefit patients, families, and health care system 2
... exercised during pregnancy needed less pain meds, study found ... during pregnancy reduces the amount of pain-killing medication requested ... that included 71 expectant mothers. , Half the ... week of aquarobics during their pregnancy, while the other ...
... the Dallas office of WHR Architects. Ms. Moran, nationally recognized ... Education, Science and Technology practice and broaden the talent base ... , "Anita,s experience and skills complement ... college and university clients," said Mark W. Vaughan AIA, ACHA, ...
... SPRINGFIELD, Mass., Nov. 21 Massachusetts Mutual Life,Insurance ... two,Co-Chief Operating Officers. , ... Officer, Executive Vice President,and Chief Investment Officer, will ... H. Reese, who remains Chairman and Chief Executive,Officer. ...
... NXTM ), a leading manufacturer of innovative ... 2008 Technology Fast 500, a,ranking of the 500 fastest ... America. Rankings are based on percentage of,fiscal year revenue ... more than 20,000 percent during this period. , ...
... by HIV/AIDS in New Jersey and Africa - , ... than 800 local Roche employees are participating in the ... support children infected and affected by HIV/AIDS in New Jersey and ... through the township of Nutley, collect donations for their efforts, and ...
... to take, has fewer side effects than chemotherapy, ... The cancer-fighting pill Iressa works as well as chemotherapy ... , Although neither therapy prolongs survival beyond eight months, ... be a better choice for patients who did not ...
Cached Medicine News:Health News:Aquarobics May Help Ease Labor 2Health News:Anita Moran AIA Joins WHR Dallas 2Health News:MassMutual Announces Promotions for Two Co-Chief Operating Officers 2Health News:MassMutual Announces Promotions for Two Co-Chief Operating Officers 3Health News:MassMutual Announces Promotions for Two Co-Chief Operating Officers 4Health News:MassMutual Announces Promotions for Two Co-Chief Operating Officers 5Health News:NxStage(R) Ranked 14th Fastest Growing Company in North America on Deloitte's 2008 Technology Fast 500 2Health News:NxStage(R) Ranked 14th Fastest Growing Company in North America on Deloitte's 2008 Technology Fast 500 3Health News:Roche Holds Sixth Annual Children's Walk in Nutley 2Health News:Roche Holds Sixth Annual Children's Walk in Nutley 3Health News:Roche Holds Sixth Annual Children's Walk in Nutley 4Health News:Iressa as Good as Chemotherapy for Lung Cancer 2Health News:Iressa as Good as Chemotherapy for Lung Cancer 3
(Date:10/31/2014)... Mich. , Oct. 31, 2014  Lycera ... modulators to treat autoimmune disease and cancer, today ... novel synthetic RORgamma agonist product candidates will be ... for Immunotherapy of Cancer (SITC) being held November ... Convention Center, National Harbor, MD.  The poster, entitled ...
(Date:10/31/2014)... -- British Journal of Urology International ... "male orgasmic dysfunction" with their doctor prior to any ... while preserving sexual function     ... paper in the British Journal of Urology International which ... with their doctors the likely impact of treatment options ...
(Date:10/31/2014)... DUBLIN , October 30, 2014 ... ) has announced the addition of the  "Process ...  conference to their offering.      (Logo: ... , Science and Risk Based Approach to Process ... Quality Risk Management FDA Process Validation ...
Breaking Medicine Technology:Lycera Announces Presentation of Data on Anti-Tumor Activity of Novel Synthetic RORgamma Agonists at Society for Immunotherapy of Cancer Meeting 2Sexual Dysfunction No Longer Inevitable When Treating Enlarged Prostate 2Process Validation in the US and EU (Workshop, London) 2Process Validation in the US and EU (Workshop, London) 3Process Validation in the US and EU (Workshop, London) 4
... 29, 2010 Reportlinker.com announces that a new ... 2010-2015 In-depth Research Report on ... http://www.reportlinker.com/p0356862/2010-2015-In-depth-Research-Report-on-China-Sodium-Fluoride-Industry.html Report SummaryBased on ... Bureau, General Administration of Custom, Ministry of Commerce ...
... Reportlinker.com announces that a new market research report ... The Outlook for Pharmaceuticals to 2012 ... Pharmaceuticals to 2012 is a new collection of management ... individual and highly-detailed analysis of each market, looking at ...
Cached Medicine Technology:Reportlinker Adds 2010-2015 In-depth Research Report on China Sodium Fluoride Industry 2Reportlinker Adds E7: The Outlook for Pharmaceuticals to 2012 2Reportlinker Adds E7: The Outlook for Pharmaceuticals to 2012 3Reportlinker Adds E7: The Outlook for Pharmaceuticals to 2012 4Reportlinker Adds E7: The Outlook for Pharmaceuticals to 2012 5
Toxoplasma IgM II ELISA....
HSV 1 & HSV 2 DFA Test....
Herpes Simplex Virus 2 IgG ELISA....
Herpes Simplex Virus 1 IgG ELISA....
Medicine Products: